Merck's Subcutaneous KEYTRUDA QLEX Approved In Japan For All Existing KEYTRUDA Indications
In brief
Merck’s new subcutaneous KEYTRUDA QLEX gets Japanese approval, enabling one‑minute injections for all current indications.
ClearTape summarizes context in-app. For the full publisher article, use Read original source above.